Press Releases

Year

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and Phase 1b; confirmed responses seen across different solid tumor types: cutaneous melanoma, ovarian

Nov 17, 2022

PDF Version

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

H ouston, Texas and Tuebingen , Germany , October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today that it has agreed to sell, by way of an

Oct 10, 2022

PDF Version

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

Company to host conf e rence call today, October 10 , at 8:30 am E D T / 2:30 pm CEST Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expression Update covers data

Oct 10, 2022

PDF Version

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

TCER ® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity in vivo and reduced T cell engager-associated toxicities as part of overall favorable in vitro

Sep 10, 2022

PDF Version

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

IMA203CD8 is a 2 nd -generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8 showed enhanced potency and prolonged anti-tumor activity mediated by activated TCR-engineered CD4 T

Aug 23, 2022

PDF Version

Immatics Announces Second Quarter 2022 Financial Results and Business Update

ACTengine ® TCR-T cell therapy targeting PRAME is enrolling patients in all three P hase 1b cohorts : IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A) , IMA203/ nivolumab checkpoint inhibitor combination (Cohort B) and IMA203CD8 2 nd gen eration monotherapy (Cohort C)

Aug 09, 2022

PDF Version

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

Tuebingen, Germany ; Houston, Texas; and Cambridge, Mass., June 7, 2022 – Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc.

Jun 07, 2022

PDF Version

Immatics Announces First Quarter 2022 Financial Results and Business Update

ACTengine® IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with 2 nd -generation IMA203CD8 granted Phase 1 clinical trial initiated with the first T cell engaging

Jun 02, 2022

PDF Version

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo ® with Bristol Myers Squibb’s technologies and oncology drug development expertise Immatics to receive upfront payment of $ 60 million and

Jun 02, 2022

PDF Version

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab 1 , a PD-1 immune checkpoint inhibitor, in patients with multiple solid tumors Initiation of the combination treatment follows

May 18, 2022

PDF Version

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors TCER® IMA401 targets MAGEA4/8 and will be developed in

May 10, 2022

PDF Version

Immatics Announces Full Year 2021 Financial Results and Corporate Update

IMA203 TCR-T candidate targeting PRAME demonstrated a 50 % objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation M ultiple IMA203 Ph ase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level , checkpoint

Mar 23, 2022

PDF Version

Press Releases

Press Contact

Press Releases